Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Three distinct signals on IVZ collided this week, and they point in opposite directions. UBS nearly doubled its price target on Invesco. Short interest jumped 26% in a single day. Both things happened at the same time.
UBS made the most striking analyst call of the week on Invesco. The firm assumed coverage with a Buy rating and lifted its price target from $21 to $41, almost doubling its estimate. RBC Capital also raised its target, from $35 to $36, maintaining Outperform.
Not everyone agrees. TD Cowen trimmed its target from $39 to $38 on 12 October, keeping its Buy rating. Evercore ISI Group cut from $37 to $34 on 9 October, sticking with In-Line.
The consensus target across all analysts now sits at $34.61. The stock closed at $29.51 on 9 October, down 8.75% over the past month. Factor scores are supportive on the analyst side: the analyst recommendation differential ranks at the 90th percentile, and EPS momentum over 90 days sits at the 84th percentile.
Short interest rose 25.9% in a single session on 9 October. It stands at 3.6% of free float, up 53.6% over the past month. That is a meaningful move in pace, though the absolute level remains moderate.
The ORTEX short score jumped to 37.9 on 9 October, from 34.6 earlier in the week. That is the sharpest single-week move in the short score over the period covered by the data.
The borrow market remains loose. Availability stands at 6,968%, meaning roughly 70 shares are available to lend for every one already borrowed. Cost to borrow is 0.49%, categorised as low. Shorts are not paying up to get in.
One other piece of context: activist investor Nelson Peltz holds a 13D position in Invesco, as last disclosed at 4.62% of the class in May 2025. That filing is over a year old. Per Schedule 13D/G rules, the stake is "as last disclosed" and Peltz could have moved below 5% without filing again.
Insider activity over the past 90 days leaned toward selling. The CFO, Laura Allison Dukes, sold over $1 million worth of shares on 4 September. Senior Managing Director Andrew Tak Shing Lo sold more than $4.6 million across two days in early September. Net insider selling over the 90-day window reached approximately $7.2 million.
Earnings are due 27 October, 15 days away.
See the live data behind this article on ORTEX.
Open IVZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
